- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07645339
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier Repair
9. juni 2026 opdateret af: L'Oreal
A Single-Center, Double-Blinded, Randomized, Placebo-Controlled, Prospective Study to Evaluate the Efficacy and Safety of a Botanical Extract in Skincare Formulations for Skin Barrier Repair on Healthy Volunteers
This is a single-center, double-blinded, placebo-controlled, prospective clinical study designed to evaluate the skin barrier repair efficacy and local tolerance of topical cosmetic formulations containing a botanical extract.
Skin barrier challenge is induced via standardized tape stripping on the volar forearm of healthy subjects.
The study will evaluate and compare the repair kinetics of two concentrations of the active formulation, a vehicle, and an untreated control zone over a 14-day application period.
Studieoversigt
Status
Aktiv, ikke rekrutterende
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Healthy female subjects will undergo a standardized skin barrier challenge (tape-stripping) on designated zones of their volar forearms at baseline.
Formulations containing different concentrations of a botanical extract (Active Formulation A and Active Formulation B), a vehicle control, and an untreated control will be assigned to the randomized zones.
Products will be applied topically twice daily for 14 days.
Skin barrier repair efficacy will be assessed using clinical gradings and instrumental measurements, including Trans-Epidermal Water Loss (TEWL) and skin hydration.
Local tolerance will be evaluated via clinical grading.
Non-invasive skin surface biomaterial collection may be performed at designated time points for skin proteomics and lipidomics analysis.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
35
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Shanghai, Kina
- L'OREAL
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Chinese women aged 35 to 60 years in good general health.
- Self-reported dry skin type.
- a hydration index < 35 and a trans-epidermal water loss (TEWL) ≥ 6g.m-2.h-1 on both anterior sides of the forearms at screening.
- Willingness to avoid excessive sun exposure and comply with all study procedures including tape stripping and biosampling.
- Bilateral forearms clear of scars, wounds, or significant pigment spots.
Exclusion Criteria:
- Current pregnancy, breastfeeding, or planning to become pregnant.
- Current smokers or history of smoking within the last 6 months (including e-cigarettes/nicotine products).
- History of facial cosmetic procedures (fillers, lasers, implants, Botox, etc.).
- Active systemic or localized skin diseases (acne, eczema, psoriasis, atopic dermatitis).
- Allergies to cosmetics, personal care products, or their ingredients.
- Excessive UV exposure or frequent sauna/water sports usage.
- Use of antihistamines, antibiotics, corticosteroids, or NSAIDs within the relevant washout periods.
- Participation in any other clinical trial within the past 30 days.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Active Formulation A
Zones applying 0.24% active formulation
|
Topical skincare formulation containing Botanical Extract (Concentration A).
Applied twice daily for 14 days.
|
|
Eksperimentel: Active Formulation B
Zones applying 0.05% active formulation
|
Topical skincare formulation containing Botanical Extract (Concentration B).
Applied twice daily for 14 days.
|
|
Placebo komparator: Vehicle Control
Zones applying the formulation base without active extract
|
Topical formulation base (identical to investigational products but without the active botanical extract).
Applied twice daily for 14 days.
|
|
Ingen indgriben: Untreated Zone
Control Zone on the forearm with no product application: Tape stripped zone left untreated to monitor natural physiological repairing kinetics
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Scoring (Erythema, Dryness, Desquamation, Roughness, Edema, PIH)
Tidsramme: Baseline, Tafter, T3h, Day 1, Day 3, Day 7, and Day 14
|
Dermatological grading of erythema, dryness, roughness, edema, desquamation and post-inflammatory hyperpigmentation using standard clinical scales
|
Baseline, Tafter, T3h, Day 1, Day 3, Day 7, and Day 14
|
|
Hydration
Tidsramme: Baseline, Tafter, Timm, T1h, T3h, Day 1, Day 3, Day 7, and Day 14
|
Hydration index measured using Corneometer
|
Baseline, Tafter, Timm, T1h, T3h, Day 1, Day 3, Day 7, and Day 14
|
|
TEWL
Tidsramme: Baseline, post-stripping (Tafter), immediately post-first application (Timm), 1 hour post-first application (T1h), 3 hours post-first application (T3h), Day 1, Day 3, Day 7, and Day 14.
|
Trans-epidermal water loss using Vapometer
|
Baseline, post-stripping (Tafter), immediately post-first application (Timm), 1 hour post-first application (T1h), 3 hours post-first application (T3h), Day 1, Day 3, Day 7, and Day 14.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Skin Structural Changes
Tidsramme: Baseline, Day 3, Day 7, and Day 14
|
Non-invasive evaluation of epidermis and dermis thickness/density using high-frequency ultrasound
|
Baseline, Day 3, Day 7, and Day 14
|
|
Epidermal Proteomic and Lipidomic Profile
Tidsramme: Baseline, Day 7
|
Characterization of stratum corneum biomarkers obtained via non-invasive tape-stripping samplings.
|
Baseline, Day 7
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
13. oktober 2025
Primær færdiggørelse (Faktiske)
3. november 2025
Studieafslutning (Anslået)
25. juli 2026
Datoer for studieregistrering
Først indsendt
9. juni 2026
Først indsendt, der opfyldte QC-kriterier
9. juni 2026
Først opslået (Faktiske)
12. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
12. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
9. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- ACR_EV_25-11289
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Impaired Barrier
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityIkke rekrutterer endnuPreserved Ratio Impaired Spirometri (PRISM)
-
The University of Hong KongQueen Mary Hospital, Hong KongRekruttering
-
Henan University of Traditional Chinese MedicineIkke rekrutterer endnuKronisk obstruktiv lungesygdom (KOL) | Preserved Ratio Impaired Spirometri (PRISM)Kina
-
University College, LondonUniversidade Federal de Sao CarlosIkke rekrutterer endnuAstma | Kronisk obstruktiv lungesygdom (KOL) | Preserved Ratio Impaired Spirometri (PRISM)Brasilien
-
Hacettepe UniversityRekrutteringKronisk obstruktiv lungesygdom (KOL) | Preserved Ratio Impaired Spirometri (PRISM)Tyrkiet (Türkiye)
Kliniske forsøg med Cosmetic Topical Product A
-
Johnson & Johnson Vision Care, Inc.Afsluttet
-
RenJi HospitalAfsluttetHepatocellulært karcinom | Leverkræft | Resistent kræftKina
-
The Maas ClinicMedicis Pharmaceutical CorporationAfsluttetIboende ældning af huden | SolelastoseForenede Stater
-
Pakinam GheetaRekrutteringKondylefrakturer | Subcondylær FrakturEgypten
-
Carruthers Dermatology CentreAllerganAfsluttet
-
AllerganAfsluttetGlabellar pandelinjerForenede Stater
-
Amir Moradi MD, MBAAllerganIkke rekrutterer endnuAldringForenede Stater
-
Walter Reed National Military Medical CenterAfsluttet
-
Merz Pharmaceuticals GmbHAfsluttetGlabellar pandelinjerDet Forenede Kongerige, Tyskland, Østrig
-
AllerganAfsluttetAnsigtsrytmer, hudfolder, tab af volumen og hudkvalitetCanada